Shin Nippon Biomedical Labor (2395 JP)

Q2 Financial Results Briefing for the Fiscal Year Ending March 2022

Speakers

• Ryoichi Nagata (Representative Chairman, President & CEO, CHO, SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.)
• Ken Takanashi (Executive Vice President, COO, SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.)
• Shinji Nitanda (Senior Executive Director of the Board, CFO, SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.)
• Hideshi Tsusaki (Senior Executive Director of the Board, President and Global BD of Preclinical Services, SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.)
• Toshiyuki Iwata (Senior Officer & Senior Director, Corporate Communications, SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.)

Analysts

• Tsuzuki (Analyst, Mizuho Securities Co., Ltd.)
• Matsubara (Analyst, Nomura Securities Co., Ltd.)
• Stephen Barker (Analyst, Jefferies Japan Limited)